Eun Jung Woo, Jang Jeong Won, Yang Hee Doo, Kim Jooyoung, Kim Sang Yean, Na Min Jeong, Shin Eunbi, Ha Jin Woong, Jeon Soyoung, Ahn Young Min, Park Won Sang, Nam Suk Woo
Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Department of Gastroenterology, Ajou University School of Medicine, Suwon 16499, Korea.
J Clin Med. 2022 Apr 11;11(8):2128. doi: 10.3390/jcm11082128.
The high morbidity rate of hepatocellular carcinoma (HCC) is mainly linked to late diagnosis. Early diagnosis of this leading cause of mortality is therefore extremely important. We designed a gene selection strategy to identify potential secretory proteins by predicting signal peptide cleavage sites in amino acid sequences derived from transcriptome data of human multistage HCC comprising chronic hepatitis, liver cirrhosis and early and overt HCCs. The gene selection process was validated by the detection of molecules in the serum of HCC patients. From the computational approaches, 10 gene elements were suggested as potent candidate secretory markers for detecting HCC patients. ELISA testing of serum showed that hyaluronan mediated motility receptor (HMMR), neurexophilin 4 (NXPH4), paired like homeodomain 1 (PITX1) and thrombospondin 4 (THBS4) are early-stage HCC diagnostic markers with superior predictive capability in a large cohort of HCC patients. In the assessment of differential diagnostic accuracy, receiver operating characteristic curve analyses showed that HMMR and THBS4 were superior to α-fetoprotein (AFP) in diagnosing HCC, as evidenced by the high area under the curve, sensitivity, specificity, accuracy and other values. In addition, comparative analysis of all four markers and AFP combinations demonstrated that HMMR-PITX1-AFP and HMMR-NXPH4-PITX1 trios were the optimal combinations for reaching 100% accuracy in HCC diagnosis. Serum proteins HMMR, NXPH4, PITX1 and THBS4 can complement measurement of AFP in diagnosing HCC and improve identification of patients with AFP-negative HCC as well as discriminate HCC from non-malignant chronic liver disease.
肝细胞癌(HCC)的高发病率主要与诊断延迟有关。因此,早期诊断这种主要死因极为重要。我们设计了一种基因筛选策略,通过预测来自人类多阶段HCC转录组数据(包括慢性肝炎、肝硬化以及早期和显性HCC)的氨基酸序列中的信号肽切割位点,来识别潜在的分泌蛋白。通过检测HCC患者血清中的分子对基因筛选过程进行了验证。从计算方法中,有10个基因元件被认为是检测HCC患者的潜在分泌标志物。血清的ELISA检测表明,透明质酸介导的运动受体(HMMR)、嗜神经素4(NXPH4)、配对样同源域1(PITX1)和血小板反应蛋白4(THBS4)是早期HCC诊断标志物,在大量HCC患者队列中具有卓越的预测能力。在鉴别诊断准确性评估中,受试者工作特征曲线分析表明,HMMR和THBS4在诊断HCC方面优于甲胎蛋白(AFP),曲线下面积、敏感性、特异性、准确性和其他值均较高。此外,对所有四种标志物与AFP组合的比较分析表明,HMMR - PITX1 - AFP和HMMR - NXPH4 - PITX1三联体是实现HCC诊断100%准确性的最佳组合。血清蛋白HMMR、NXPH4、PITX1和THBS4可在诊断HCC时补充AFP的检测,并改善对AFP阴性HCC患者的识别,以及区分HCC与非恶性慢性肝病。